Literature DB >> 15625970

Conclusions and recommendations of the Ad Hoc Advisory Committee on Poliomyelitis Eradication, Geneva, 21-22 September 2004.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15625970

Source DB:  PubMed          Journal:  Wkly Epidemiol Rec        ISSN： 0049-8114


× No keyword cloud information.
  6 in total

1.  The risks, costs, and benefits of possible future global policies for managing polioviruses.

Authors:  Kimberly M Thompson; Radboud J Duintjer Tebbens; Mark A Pallansch; Olen M Kew; Roland W Sutter; R Bruce Aylward; Margaret Watkins; Howard E Gary; James Alexander; Hamid Jafari; Stephen L Cochi
Journal:  Am J Public Health       Date:  2008-05-29       Impact factor: 9.308

2.  Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs).

Authors:  Radboud J Duintjer Tebbens; Mark A Pallansch; Jong-Hoon Kim; Cara C Burns; Olen M Kew; M Steven Oberste; Ousmane M Diop; Steven G F Wassilak; Stephen L Cochi; Kimberly M Thompson
Journal:  Risk Anal       Date:  2013-03-07       Impact factor: 4.000

3.  The human qualities needed to complete the global eradication of polio.

Authors:  Dermot Maher
Journal:  Bull World Health Organ       Date:  2013-01-24       Impact factor: 9.408

Review 4.  The final stages of the global eradication of poliomyelitis.

Authors:  Nicholas C Grassly
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-06-24       Impact factor: 6.237

Review 5.  The role of research in viral disease eradication and elimination programs: lessons for malaria eradication.

Authors:  Joel G Breman; Ciro A de Quadros; Walter R Dowdle; William H Foege; Donald A Henderson; T Jacob John; Myron M Levine
Journal:  PLoS Med       Date:  2011-01-25       Impact factor: 11.069

Review 6.  Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: systematic review and meta-analysis.

Authors:  Nicholas C Grassly
Journal:  J Infect Dis       Date:  2014-03-14       Impact factor: 5.226
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.